Exact Sciences halted ahead of FDA panel meeting for Cologuard

Exact Sciences' (EXAS) shares have been halted ahead of a meeting of an FDA committee to discuss the company's premarket approval application for its Cologuard screening test for colorectal cancer.

The panel is due to start the meeting at 8 am ET.

Trial results showed that compared with colonoscopy, the test is 92% sensitive for cancer stages I and II, and 69% for precancerous polyps containing high-grade dysplasia (highest cancer risk). (PR)

FDA briefing materials.

From other sites
Comments (2)
  • jpmj4847
    , contributor
    Comments (571) | Send Message
    Yes, a closer step in early treatment of this deadly cancer. Go EXAS ! jpmj4847
    27 Mar 2014, 06:33 PM Reply Like
  • 6322651
    , contributor
    Comments (13) | Send Message
    I read an article about EXAS, in which the main points were: 1. the Cologuard screening test by EXAS was too costly compare to other test even it pass the FDA; 2.the presented test results were questionable; 3. unfair set up for claim of equity between for the insiders and the investors.
    28 Mar 2014, 03:47 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs